Novartis Reports Results of Ofatumumab (OMB157) in P-III ASCLEPIOS I and II Studies for Multiple Sclerosis

 Novartis Reports Results of Ofatumumab (OMB157) in P-III ASCLEPIOS I and II Studies for Multiple Sclerosis

Novartis’ Cosentyx (secukinumab) Receives NMPA’s (CFDA) Approval for Patients with Plaque Psoriasis in Adults

Shots:

  • The P-III ASCLEPIOS I and II (NCT02792218 and NCT02792231) studies involve assessing of Ofatumumab (20mg, SC, monthly) vs Aubagio (teriflunomide, 14mg, qd) in 1,882 patients with MS aged 18-55yrs. across 37 countries
  • The P-III ASCLEPIOS I and II studies resulted in meetings their 1EPs & 2EPs i.e, @30mos. reduction in annualized relapse rate evaluated by ARR & delayed time to disability progression, @6mos. confirmed disability improvement respectively, additional 2EPs will be presented at ECTRIMS
  • Ofatumumab is mAb targeting CD20 molecule on the B-cell surface and inducing potent B-cell lysis and depletion with its expected initiation of regulatory submission in H2’19. In Dec’2015, Genmab granted rights for ofatumumab in all indications including MS to Novartis

Click here to­ read full press release/ article | Ref: Novartis | Image: WSJ

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post